Market open · Delayed intraday data · 9:39 AM ET
Last update: Nov 19, 2026, 9:32 AM ET
Edwards Lifesciences Corporation
$104.82▼ 0.39% today
Market Open

Why Edwards Lifesciences Corporation (EW) stock moved

No significant move on Nov 18, 2026 (−0.2%, close-to-close). Latest notable session: Nov 9, 2026.

Latest session▲ 2.5% · Nov 9, 2026 close

Why Edwards Lifesciences Corporation (EW) rose 2.5% on November 9, 2026

Edwards Lifesciences Corporation (EW) rose 2.5% on November 9, 2026, closing at $104.71 versus $102.14 the prior session (close-to-close, from daily closes). Driven by continued positive momentum from its strong Q3 2026 results ($1.72B sales, $0.80 adjusted EPS beat), raised full-year guidance, and a wave of analyst price-target upgrades from UBS, JPMorgan, Citigroup, and Truist Financial. Volume was normal at 1.09x the historical average for this time of day. Source: defenseworld.net.

Updated
Prior close
$102.14
Nov 9, 2026 close
$104.71
Change (close-to-close)
+$2.57
+2.52%
As first detected · Nov 9, 2026, 12:12 PM ET

Edwards Lifesciences rose 2.14% to $104.33, driven by continued positive momentum from its strong Q3 2026 results ($1.72B sales, $0.80 adjusted EPS beat), raised full-year guidance, and a wave of analyst price-target upgrades from UBS, JPMorgan, Citigroup, and Truist Financial. Volume was normal at 1.09x the historical average for this time of day.

What to watch next: EW earnings scheduled for 2027-02-09 (consensus estimate: $0.66 EPS); monitor any further clinical trial readouts or approval announcements for TAVR/TMTT therapies.

Source: defenseworld.net · percentages in this note are as captured at detection; the confirmed close-to-close move is shown above.

Earlier sessions that moved EW

  1. +4.4%Announced positive clinical trial results.
  2. −2.6%We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found.
  3. +2.9%Ahead of Q3 earnings (Seeking Alpha).
  4. +4.1%Driven by expanded Medicare coverage for TAVR (transcatheter aortic valve replacement) procedures to asymptomatic patients and management presentations at the Deutsche Bank 2026 Healthcare Summit.
  5. −2.8%As broader market weakness—driven by rising Treasury yields and macroeconomic headwinds—pressured the stock alongside valuation concerns and recent insider selling activity (web_catalyst).
  6. −3.5%Market data indicates routine day-to-day fluctuations and normal trading behavior within recent ranges, per web search synthesis.

Edwards Lifesciences Corporation (EW) shares fell 0.4% to $104.82 as of November 19, 2026, a slight decline from the prior close of $105.23. BestStocks flagged the session as a major change for EW. Below, we break down what changed for EW, why it matters for investors, how the stock reacted, and the catalysts on the calendar.

What happened

EW fell 0.4% to $104.81

EW fell 0.4% in its latest session, moving from $105.23 to $104.82.

ValuationWeak confidence
Rel. volume
0.0×
Below Avg
Vs peers
—
No comparable peers
Market cap
$60.3B
New York Stock Exchange
Analyst target
$109
+3.7% vs price
Price chart
Oct 19 – Nov 19
VNVFE$87$97$107Oct 19Oct 27Nov 4Nov 11Nov 19
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details

What it means for Edwards Lifesciences Corporation investors

For Edwards Lifesciences Corporation investors, the recent signals add up to a bearish shift. On the constructive side: Positive price momentum. Weighing against that: Negative session, down 0.4%; Edwards Lifesciences declined 2.34% to $87.80 in early intraday trading with no major negative catalyst identified. Wall Street's consensus price target sits at $108.70, implying +3.7% upside from $104.82. Over the past 90 days analysts logged 1 upgrade and 0 downgrades. BestStocks rates the overall signal quality weak (27/100). With earnings roughly 82 days out, the next report is the most likely near-term test of the move.

EW price reaction

EW last traded at $104.82, down $0.42 (-0.39%) from the previous close of $105.23. The session traded on 0.0× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $87.22 and $107.15, and it currently sits about 88% of the way up that band.

Bullish and bearish analyst opinions on Edwards Lifesciences Corporation (EW)

The consensus analyst price target on Edwards Lifesciences Corporation (EW) is $108.70, 3.7% above the recent $104.82. Over the past 90 days analysts logged 1 upgrade, 14 maintains, and 0 downgrades. Here is how the bullish and bearish cases on EW line up.

The bullish case

  • Wall Street's consensus price target of $108.70 implies +3.7% upside from $104.82.
  • The Street's most bullish target is $120.00 (+14.5%).
  • 1 analyst upgrade in the past 90 days, most recently Truist Securities to Buy (2026-11-04).
  • Positive price momentum.

The bearish case

  • The most bearish analyst target is $100.00 (-4.6%).
  • Negative session, down 0.4%.
  • Edwards Lifesciences declined 2.34% to $87.80 in early intraday trading with no major negative catalyst identified.
Bull vs bear balanceBearish Shift
BearishNeutralBullish

Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.

Analyst price targets and ratings are FMP consensus figures as of Nov 19, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.

Analyst expectations
Consensus target: $109+3.7%
↑ 1 upgrades= 14 maintains
TD Cowen maintained Buy · 2026-11-11
SEC filings watch
10-Q2026-11-04
Quarterly financial results
medium
8-K2026-11-04
Material event — review for impact
high
8-K2026-08-28
Material event — review for impact
high
10-Q2026-08-04
Quarterly financial results
medium
Peer context
EW-0.4%

Previous notable changes for EW

Filings2026-11-04+4.4%
Edwards Lifesciences Corporation (EW) filed an 8-K on November 4, 2026. The filing content was not disclosed in available sources.
Material / Earnings2026-11-04+4.4%
Edwards Lifesciences Corporation (EW) reported EPS of $0.80 vs. $0.74 consensus estimate, beating by 8.5%.
News2026-11-02+1.4%
Edwards' PASCAL tricuspid repair system achieved superiority over medical therapy alone in CLASP II TR trial.
Activity2026-10-29+2.9%via Seeking Alpha ↗
Edwards Lifesciences rose 2.58% to $94.14, buoyed by positive sentiment around its cardiovascular product portfolio ahead of Q3 earnings (Seeking Alpha). Volume of 843,918 shares ran at 1.36x the expected average for this point in the session—normal trading intensity with no unusual accumulation.
Upcoming catalysts & outlook
Next earnings
2027-02-09 (est.)
in 82 days
Earnings Release
2027-02-09
High impact
Thesis shift
Bearish Shift
bearish signal
Risk level
Medium
from change events

Frequently asked questions about EW

Why did Edwards Lifesciences Corporation (EW) stock move?

Edwards Lifesciences Corporation (EW) rose 2.5% on November 9, 2026, closing at $104.71 versus $102.14 the prior session (close-to-close, from daily closes). Driven by continued positive momentum from its strong Q3 2026 results ($1.72B sales, $0.80 adjusted EPS beat), raised full-year guidance, and a wave of analyst price-target upgrades from UBS, JPMorgan, Citigroup, and Truist Financial. Volume was normal at 1.09x the historical average for this time of day. Source: defenseworld.net.

How much did EW stock fall?

EW lost 0.39% ($0.42) versus the prior close of $105.23, last trading at $104.82 on 0.0× average volume.

When is Edwards Lifesciences Corporation's next earnings date?

EW's next earnings report is estimated for 2027-02-09 — about 82 days away.

What is the analyst price target for EW?

The consensus analyst price target for EW is $108.70, about 3.7% above the current $104.82. Over the past 90 days, analysts recorded 1 upgrade, 14 maintains, and 0 downgrades.

How BestStocks tracks EW

This page is generated automatically by BestStocks' change-detection system after its price and volume cleared EW-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for EW, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of November 19, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.

Data sources
FMP real-time & historical price dataSEC EDGAR filingsFMP earnings & estimatesAnalyst ratings & price targets (FMP)Earnings calendar (FMP)
Educational research tool — not personalized investment advice. Data may be delayed.